Analyst Price Target is $55.00
▲ +66.01% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Vogenx in the last 3 months. The average price target is $55.00, with a high forecast of $55.00 and a low forecast of $55.00. The average price target represents a 66.01% upside from the last price of $33.13.
Current Consensus is
Buy
The current consensus among 1 investment analysts is to buy stock in Vogenx.
Vogenx
Vogenx Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company's product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome. Vogenx Inc. is based in RALEIGH, NC.
Read More